Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, single-blind, placebo-controlled, dose-escalation phase I study to evaluate safety, pharmacological characteristics and pharmacokinetics of NC-2500 in healthy volunteers with single and multiple dosing.

Trial Profile

A randomized, single-blind, placebo-controlled, dose-escalation phase I study to evaluate safety, pharmacological characteristics and pharmacokinetics of NC-2500 in healthy volunteers with single and multiple dosing.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs NC-2500 (Primary)
  • Indications Gout; Hyperuricaemia
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 24 Oct 2018 Results assessing safety, tolerability, pharmacokinetics and pharmacodynamics (PD) profiles of NC-2500, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 01 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top